शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSEMEDI-CAPS LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 6 Aug, 2026 · 16:48 IST

Medi-Caps Q1 FY27: net loss of Rs 223 lakh; CFO and Director appointed

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.1%Reaction day
₹26.55
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-2.1% vs market
Pharmaceuticals peers, median of 168sector+0.3%-2.4% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.1+0.0-2.1+0.3-2.4
Next day
+1.2-0.0+1.3+0.7+0.5
2d
-0.6-0.2-0.4+0.6-1.2
3d
+0.9+0.2+0.8+0.4+0.6
4d
-0.9+0.3-1.2+1.2-2.1
5d
+3.4+0.4+3.0+0.2+3.2
1w
—+0.9—+0.2—
15d
—+1.6—+1.1—
1m
—+2.0—+2.4—
2m
—+0.6—+1.6—
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medi-Caps board approved Q1 FY27 results on 06 Aug 2026. Consolidated revenue was Rs 278.69 lakh with net loss of Rs 223.29 lakh. Standalone revenue was Rs 10.49 lakh with loss of Rs 58.96 lakh. Pharma segment loss was Rs 164.33 lakh. Subsidiary Medgel reported Rs 223.30 lakh loss. Clean auditor review. Akshit Garg is new CFO, Saloni Garg is new Whole-Time Director, CMD Alok K Garg re-appointed for 3 years. AGM on 22 September via video conferencing.

Likely market impact

Consolidated net loss narrowed YoY but remains negative. Pharma segment and Medgel subsidiary continue to drag profitability. CFO and Director changes effective from 07 August.